跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Sandoz Gmbh

首页临床试验发起方与机构Sandoz Gmbh

Sandoz Gmbh

ACTIVE

Costa Ricawww.sandoz.atSubsidiary

隶属于 Sandoz International GmbH

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

22

18 进行中

药物批准

187

批准总数

监管机构

6

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

12

54.5%

3 期

4

18.2%

试验状态分布

进行中（未招募）

18

81.8%

已完成

4

18.2%

相关临床试验

该机构主办的试验（22）

A study to evaluate the Efficacy and Safety of LA-EP2006 and NeulastaÂ® in patients with breast cancer.

Oct 2012302 名受试者

Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®

进行中（未招募）

Jul 2012308 名受试者

A study comparing the efficacy and safety of LA-EP2006 and Neulasta in breast cancer patients being treated with types of chemotherapy which decrease white blood cells.

进行中（未招募）

May 2012302 名受试者

A study to evaluate the Efficacy and Safety of LA-EP2006 and NeulastaÂ® in patients with breast cancer.

Mar 2012302 名受试者

A study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients being treated with types of chemotherapy which decrease white blood cells

进行中（未招募）

Dec 2011192 名受试者

A study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients being treated with types of chemotherapy which decrease white blood cells

进行中（未招募）

Dec 2011192 名受试者

Twelve-month study on the immunogenicity (i.e. the ability of the study medication to provoke an immune response), safety and efficacy of the study medication Zarzio®/Filgrastim HEXAL® in patients with severe chronic neutropenia

进行中（未招募）

Dec 201140 名受试者

A study comparing the efficacy and safety of EP2006 and Neupogen® inbreast cancer patients being treated with types of chemotherapy whichdecrease white blood cells

进行中（未招募）

Nov 2011192 名受试者

第 1 页，共 3 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

13

药物批准

EMA

European Medicines Agency

47

药物批准

PHILIPPINES

Philippines FDA

13

药物批准

SFDA

Saudi Food and Drug Authority

13

药物批准

NPRA

National Pharmaceutical Regulatory Agency

13

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

88

药物批准

近期批准

ONDIBTA 100 UNIDADES/ML SOLUCION INYECTABLE EN PLUMA PRECARGADA

Curam Film Coated Tablets 625mg

Curam powder for oral suspension 312.5mg/5ml

Binocrit 40, 000 IU/1 ml solution for injection in a pre-filled syringe

CEFAZOLIN SANDOZ 1G VIAL

Zinnat Tablets 500mg

Binocrit 4,000 IU/0.4 ml solution for injection in a pre-filled syringe

OSPAMOX 250MG/5ML GRANULES FOR ORAL SUSPENSION

Binocrit 10 000 IU/1 ml solution for injection in a pre-filled syringe

OSPAMOX 1000MG FILM-COATED TABLET

资讯

暂无资讯文章

本页目录

概览
相关临床试验22
药物批准187
资讯

返回机构列表